Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PRV311
- Development stage
- Preclinical
- Lead developer
- Privo Technologies
- Modality
- Nanoparticles → Drug Delivery Systems
- Administration
- Topical
01
Overview
PRV311 is a nanoengineered, localized treatment developed by Privo Technologies, Inc. for cervical cancer. It is designed specifically for use in low- and middle-income countries (LMICs) to address the high prevalence and mortality rates of cervical cancer in these regions. The treatment aims to minimize the need for surgery, reduce risks such as preterm birth, and require fewer patient visits, providing a long-lasting alternative. The drug's development is supported by a Direct-to-Phase II SBIR contract from the National Cancer Institute (NCI) and is based on Privo's PRV nanoengineered platform technology, which originated from MIT.
Beyond the preview
Go deeper on PRV311.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PRV311.